Home Cart Sign in  
Chemical Structure| 944118-01-8 Chemical Structure| 944118-01-8

Structure of Peficitinib
CAS No.: 944118-01-8

Chemical Structure| 944118-01-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Peficitinb is an oral Janus kinase (JAK) inhibitor. Peficitinib inhibits JAK1, JAK2, JAK3 and Tyk2 enzyme activities with IC50s of 3.9, 5.0, 0.71 and 4.8 nM, respectively, and has moderate selectivity for JAK3 inhibition.

Synonyms: ASP015K; JNJ-54781532

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Peficitinib

CAS No. :944118-01-8
Formula : C18H22N4O2
M.W : 326.39
SMILES Code : N([C@H]1[C@@]2(CC3(O)C[C@]1(CC(C2)C3)[H])[H])C4=C5C(=NC=C4C(N)=O)NC=C5
Synonyms :
ASP015K; JNJ-54781532
MDL No. :MFCD28502035

Safety of Peficitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Peficitinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK2

In Vitro:

Cell Line
Concentration Treated Time Description References
PBMC 5 µM 24 h Peficitinib-treated RA FLS-conditioned medium reduced PBMC migration. PMC6627593
THP-1 5 µM 24 h Peficitinib-treated RA FLS-conditioned medium reduced THP-1 migration. PMC6627593
RA FLS 0.1, 1, 5 µM 24 h Peficitinib suppressed the phosphorylation of STAT1, STAT3, and STAT5 in RA FLS in a concentration-dependent manner. PMC6627593
THP-1 cells 5 μM 90 min Peficitinib-treated RA FLS-conditioned medium reduced THP-1 cell migration. PMC6627593
Peripheral blood mononuclear cells (PBMC) 5 μM 90 min Peficitinib-treated RA FLS-conditioned medium reduced PBMC migration. PMC6627593
Rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) 0.1, 1, 5 μM 24 h Peficitinib suppressed phosphorylation of STAT1, STAT3, and STAT5 in RA FLS in a concentration-dependent manner. PMC6627593
PsAFLS (Psoriatic Arthritis Synovial Fibroblasts) 5 µM 24 h To evaluate the effect of Peficitinib on OSM-induced inflammatory responses in PsAFLS. Results showed that Peficitinib significantly inhibited the secretion of MCP-1 and IL-6 but had no significant effect on IL-8. Additionally, Peficitinib significantly reduced the secretion of MMP-1, MMP-3, and MMP-9 and inhibited cell invasion and migration capacity. PMC8264423
Rheumatoid arthritis synovial fibroblasts (RASF) 1 µM and 5 µM 17 h Peficitinib at 5 µM significantly reduced the release of IL-6, MMP-3, CXCL8, and CXCL1 from IL-1β-activated RASF. Additionally, peficitinib was the only JAK inhibitor that suppressed RASF proliferation at 1 µM. PMC6448044

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03971253 Rheumatoid Arthritis (RA) RECRUITING 2025-12-31 Site JP00023, Aichi, Japan|Sit... More >>e JP00005, Akita, Japan|Site JP00002, Aomori, Japan|Site JP00012, Chiba, Japan|Site JP00038, Ehime, Japan|Site JP00018, Fukui, Japan|Site JP00040, Fukuoka, Japan|Site JP00007, Fukushima, Japan|Site JP00021, Gifu, Japan|Site JP00010, Gunma, Japan|Site JP00034, Hiroshima, Japan|Site JP00001, Hokkaido, Japan|Site JP00028, Hyogo, Japan|Site JP00008, Ibaraki, Japan|Site JP00017, Ishikawa, Japan|Site JP00003, Iwate, Japan|Site JP00037, Kagawa, Japan|Site JP00046, Kagoshima, Japan|Site JP00014, Kanagawa, Japan|Site JP00039, Kochi, Japan|Site JP00043, Kumamoto, Japan|Site JP00026, Kyoto, Japan|Site JP00024, Mie, Japan|Site JP00004, Miyagi, Japan|Site JP00045, Miyazaki, Japan|Site JP00020, Nagano, Japan|Site JP00042, Nagasaki, Japan|Site JP00029, Nara, Japan|Site JP00015, Niigata, Japan|Site JP00044, Oita, Japan|Site JP00033, Okayama, Japan|Site JP00047, Okinawa, Japan|Site JP00027, Osaka, Japan|Site JP00041, Saga, Japan|Site JP00011, Saitama, Japan|Site JP00025, Shiga, Japan|Site JP00032, Shimane, Japan|Site JP00022, Shizuoka, Japan|Site JP00009, Tochigi, Japan|Site JP00036, Tokushima, Japan|Site JP00013, Tokyo, Japan|Site JP00031, Tottori, Japan|Site JP00016, Toyama, Japan|Site JP00030, Wakayama, Japan|Site JP00006, Yamagata, Japan|Site JP00035, Yamaguchi, Japan|Site JP00019, Yamanashi, Japan Less <<
NCT01929577 Bioavailability of ASP015K|Hea... More >>lthy Subjects|Pharmacokinetics of ASP015K|Food Effect of ASP015K Less << PHASE1 COMPLETED 2025-08-13 Parexel - Early Phase Clinical... More >> Unit, Baltimore, Maryland, 21225, United States Less <<
NCT01406132 Healthy Subjects|Pharmacokinet... More >>ics of ASP015K Less << PHASE1 COMPLETED 2025-01-10 Covance Clinical Research Unit... More >> (CCRU), Madison, Wisconsin, 53704, United States Less <<
NCT01486017 Bioavailability of ASP015K|Pha... More >>rmacokinetics of ASP015K|Healthy Subjects Less << PHASE1 COMPLETED 2025-09-11 Covance, Dallas, Texas, 75247,... More >> United States Less <<
NCT01484964 Pharmacokinetics of ASP015K|Bi... More >>oavailability of ASP015K|Healthy Subjects Less << PHASE1 COMPLETED 2025-10-11 PAREXEL, Glendale, California,... More >> 91206, United States Less <<
NCT01638013 Arthritis, Rheumatoid PHASE3 COMPLETED 2019-09-30 JP00037, Nagoya, Aichi, Japan|... More >>JP00109, Nagoya, Aichi, Japan|JP00130, Nagoya, Aichi, Japan|JP00175, Nagoya, Aichi, Japan|JP00066, Okazaki, Aichi, Japan|JP00140, Toyoake, Aichi, Japan|JP00108, Toyohashi, Aichi, Japan|JP00170, Toyohashi, Aichi, Japan|JP00156, Toyota, Aichi, Japan|JP00068, Yatomi, Aichi, Japan|JP00180, Asahi, Chiba, Japan|JP00166, Funabashi, Chiba, Japan|JP00102, Kamagaya, Chiba, Japan|JP00115, Narashino, Chiba, Japan|JP00138, Yotsukaido, Chiba, Japan|JP00120, Iizuka, Fukuoka, Japan|JP00040, Kitakyushu, Fukuoka, Japan|JP00119, Kitakyushu, Fukuoka, Japan|JP00071, Kurume, Fukuoka, Japan|JP00106, Kurume, Fukuoka, Japan|JP00033, Takasaki, Gunma, Japan|JP00163, Higashihiroshima, Hiroshima, Japan|JP00124, Tomakomai, Hokaido, Japan|JP00026, Asahikawa, Hokkaido, Japan|JP00090, Hakodate, Hokkaido, Japan|JP00172, Kitami, Hokkaido, Japan|JP00125, Kushiro, Hokkaido, Japan|JP00001, Sapporo, Hokkaido, Japan|JP00002, Sapporo, Hokkaido, Japan|JP00003, Sapporo, Hokkaido, Japan|JP00031, Sapporo, Hokkaido, Japan|JP00038, Sapporo, Hokkaido, Japan|JP00114, Sapporo, Hokkaido, Japan|JP00158, Sapporo, Hokkaido, Japan|JP00056, Akashi, Hyogo, Japan|JP00069, Himeji, Hyogo, Japan|JP00136, Itami, Hyogo, Japan|JP00041, Kato, Hyogo, Japan|JP00012, Kobe, Hyogo, Japan|JP00042, Kobe, Hyogo, Japan|JP00092, Kobe, Hyogo, Japan|JP00154, Kobe, Hyogo, Japan|JP00171, Kobe, Hyogo, Japan|JP00117, Nishinomiya, Hyogo, Japan|JP00181, Hitachinaka, Ibaraki, Japan|JP00107, Hitachi, Ibaraki, Japan|JP00073, Koga, Ibaraki, Japan|JP00054, Mito, Ibaraki, Japan|JP00039, Tsukuba, Ibaraki, Japan|JP00034, Komatsu, Ishikawa, Japan|JP00179, Komatsu, Ishikawa, Japan|JP00028, Morioka, Iwate, Japan|JP00049, Morioka, Iwate, Japan|JP00088, Kida-gun, Kagawa, Japan|JP00084, Isehara, Kanagawa, Japan|JP00058, Kawasaki, Kanagawa, Japan|JP00141, Sagamihara, Kanagawa, Japan|JP00096, Yokohama, Kanagawa, Japan|JP00045, Zushi, Kanagawa, Japan|JP00019, Koshi, Kumamoto, Japan|JP00057, Tamana, Kumamoto, Japan|JP00168, Yokkaichi, Mie, Japan|JP00023, Miyagi-gun, Miyagi, Japan|JP00169, Osaki, Miyagi, Japan|JP00004, Sendai, Miyagi, Japan|JP00027, Sendai, Miyagi, Japan|JP00036, Sendai, Miyagi, Japan|JP00105, Sendai, Miyagi, Japan|JP00151, Sendai, Miyagi, Japan|JP00050, Hyuga, Miyazaki, Japan|JP00129, Matsumoto, Nagano, Japan|JP00162, Isehaya, Nagasaki, Japan|JP00101, Omura, Nagasaki, Japan|JP00103, Omura, Nagasaki, Japan|JP00153, Sasebo, Nagasaki, Japan|JP00094, Kashihara, Nara, Japan|JP00025, Nagaoka, Niigata, Japan|JP00144, Shibata, Niigata, Japan|JP00064, Beppu, Oita, Japan|JP00051, Setouchi, Okayama, Japan|JP00011, Hannan, Osaka, Japan|JP00134, Higashiosaka, Osaka, Japan|JP00078, Kawachinagano, Osaka, Japan|JP00137, Sakai, Osaka, Japan|JP00070, Suita, Osaka, Japan|JP00086, Suita, Osaka, Japan|JP00146, Suita, Osaka, Japan|JP00061, Toyonaka, Osaka, Japan|JP00075, Ureshino, Saga, Japan|JP00126, Gyoda, Saitama, Japan|JP00007, Hiki-gun, Saitama, Japan|JP00060, Kawagoe, Saitama, Japan|JP00161, Kawagoe, Saitama, Japan|JP00062, Kawaguchi, Saitama, Japan|JP00052, Sayama, Saitama, Japan|JP00008, Tokorozawa, Saitama, Japan|JP00133, Kakegawa, Shizuoka, Japan|JP00077, Kanuma, Tochigi, Japan|JP00145, Shimotsuke, Tochigi, Japan|JP00024, Bunkyo-ku, Tokyo, Japan|JP00043, Bunkyo-ku, Tokyo, Japan|JP00143, Bunkyo-ku, Tokyo, Japan|JP00149, Bunkyo-ku, Tokyo, Japan|JP00152, Bunkyo-ku, Tokyo, Japan|JP00095, Chiyoda-ku, Tokyo, Japan|JP00099, Chiyoda-ku, Tokyo, Japan|JP00142, Chuo-ku, Tokyo, Japan|JP00063, Hachioji, Tokyo, Japan|JP00053, Kiyose, Tokyo, Japan|JP00072, Meguro-ku, Tokyo, Japan|JP00083, Meguro-ku, Tokyo, Japan|JP00148, Ota-ku, Tokyo, Japan|JP00100, Setagaya-ku, Tokyo, Japan|JP00081, Shibuya-ku, Tokyo, Japan|JP00032, Shinjuku-ku, Tokyo, Japan|JP00021, Sumida-ku, Tokyo, Japan|JP00010, Takaoka, Toyama, Japan|JP00155, Nishimuro-gun, Wakayama, Japan|JP00104, Shimonoseki, Yamaguchi, Japan|JP00047, Shunan, Yamaguchi, Japan|JP00176, Fukui, Japan|JP00018, Fukuoka, Japan|JP00020, Fukuoka, Japan|JP00035, Fukuoka, Japan|JP00059, Fukuoka, Japan|JP00076, Fukuoka, Japan|JP00131, Fukuoka, Japan|JP00164, Fukuoka, Japan|JP00165, Fukushima, Japan|JP00013, Hiroshima, Japan|JP00014, Hiroshima, Japan|JP00015, Hiroshima, Japan|JP00016, Hiroshima, Japan|JP00055, Hiroshima, Japan|JP00065, Kagoshima, Japan|JP00074, Kagoshima, Japan|JP00167, Kagoshima, Japan|JP00093, Kochi, Japan|JP00022, Kumamoto, Japan|JP00046, Kumamoto, Japan|JP00085, Kyoto, Japan|JP00123, Kyoto, Japan|JP00159, Kyoto, Japan|JP00122, Miyazaki, Japan|JP00080, Nagano, Japan|JP00174, Nagano, Japan|JP00098, Nagasaki, Japan|JP00112, Nagasaki, Japan|JP00147, Nagasaki, Japan|JP00006, Niigata, Japan|JP00017, Oita, Japan|JP00118, Okayama, Japan|JP00150, Osaka, Japan|JP00157, Osaka, Japan|JP00044, Shizuoka, Japan|JP00089, Shizuoka, Japan|JP00135, Shizuoka, Japan|JP00009, Toyama, Japan|JP00139, Toyama, Japan|KR00504, Daegu, Korea, Republic of|KR00505, Gwangju, Korea, Republic of|KR00506, Incheon, Korea, Republic of|KR00508, Jeonju, Korea, Republic of|KR00501, Seoul, Korea, Republic of|KR00502, Seoul, Korea, Republic of|KR00509, Seoul, Korea, Republic of|KR00511, Seoul, Korea, Republic of|KR00507, Suwon, Korea, Republic of|TW00709, Kaohsiung, Taiwan|TW00710, Taichung, Taiwan|TW00712, Tainan, Taiwan|TW00701, Taipei, Taiwan|TW00702, Taipei, Taiwan|TW00711, Taipei, Taiwan|TW00703, Taoyuan, Taiwan Less <<
NCT02603497 Patients With Impaired Renal F... More >>unction Less << PHASE1 COMPLETED 2016-12-19 Site JP00001, Tokyo, Japan|Sit... More >>e JP00002, Tokyo, Japan Less <<
NCT02586194 Patients With Impaired Hepatic... More >> Function Less << PHASE1 COMPLETED 2016-09-27 Site JP00001, Fukuoka, Japan|S... More >>ite JP00003, Kanagawa, Japan|Site JP00002, Tokyo, Japan|Site JP00004, Tokyo, Japan|Site JP00005, Tokyo, Japan|Site JP00006, Tokyo, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.32mL

3.06mL

1.53mL

30.64mL

6.13mL

3.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories